Crystalline forms of trofinetide
This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.
1 . Crystalline trofinetide·xH 2 O, wherein x is about 2 to about 4, characterized as having:
(1) a powder x-ray diffraction pattern with peaks at 6.8, 11.5, 12.6, 13.8, and 16.8 degrees 2Θ using Cu Kα radiation, wherein the 20 values are ±0.2 degrees 2Θ; and/or
(ii) a powder x-ray diffraction pattern with d-spacings at 13.1, 7.7, 7.0, 6.4, and 5.3 Å using Cu Kα radiation; and/or
(iii) a FT-Raman spectrum with peaks at 2989, 2934, 2883, 1685, 1637, 1459, and 930 cm −1 , wherein the cm −1 values are +4 cm −1 ; and/or
(iv) a low frequency (LF) Raman spectrum with peaks at 13, 24, 67, and 77 cm −1 , wherein the cm −1 values are ±4 cm −1 ; and/or
(v) a 13C solid-state nuclear magnetic resonance spectrum with peaks at 179.7, 177.9, 177.5, 177.2, 177.0, 165.3, 164.9, 164.8, 67.8, 67.4, 58.6, 58.2, 46.8, 40.3, 33.3, 25.3, 23.5, and 21.1 ppm, wherein the ppm values are ±3 μm; and/or
(vi) a 13C solid-state nuclear magnetic resonance spectrum with 18 peaks, wherein the Δ from the furthest downfield peak to: (i) the second furthest downfield peak is 1.8 ppm; (ii) the third furthest downfield peak is 2.2 ppm; (iii) the fourth furthest downfield peak is 2.5 ppm; (iv) the fifth furthest downfield peak is 2.7 ppm (v) the sixth furthest downfield peak is 14.4 ppm; (vi) the seventh furthest downfield peak is 14.8 ppm; (vii) the eighth furthest downfield peak is 14.9 ppm; (viii) the ninth furthest downfield peak is 111.9 ppm; (ix) the tenth furthest downfield peak is 112.3 ppm; (x) the eleventh furthest downfield peak is 121.1 ppm; (xi) the twelfth furthest downfield peak is 121.5 ppm; (xii) the thirteenth furthest downfield peak is 133.1 ppm; (xiii) the fourteenth furthest downfield peak is 139.4 ppm; (xiv) the fifteenth furthest downfield peak is 146.3 ppm; (xv) the sixteenth furthest downfield peak is 154.6 ppm; (xvi) the seventeenth furthest downfield peak is 156.2 ppm; and/or (xvii) the Δ from the furthest downfield peak to the furthest upfield peak is 158.6 ppm, or any combination thereof; and/or
(vii) a melting point with an onset temperature of 71.71° C. and a peak temperature of 72.06° C. based on differential scanning calorimetry; and/or
(viii) an infrared (IR) spectrum with peaks at 1678, 1636, 1589, 1525, 1214, and 1196 cm −1 , wherein the cm −1 values are ±4 cm −1 ; and/or
(ix) a near-infrared (NIR) spectrum with peaks at 5145, 4630, and 4423 cm −1 , wherein the cm −1 values are ±4 cm −1 ; and/or
a combination thereof.
2 . The crystalline trofinetide·xH 2 O of claim 1 , characterized as having a powder x-ray diffraction pattern with peaks at 6.8, 11.5, 12.6, 13.8, and 16.8 degrees 2Θ using Cu Kα radiation, wherein the 2Θ values are ±0.2 degrees 2Θ.
3 . The crystalline trofinetide·xH 2 O of claim 2 further characterized as having a powder x-ray diffraction pattern with peaks at 22.3, 23.6, 25.3 and/or 28.1 degrees 2Θ using Cu Kα radiation, wherein the 2Θ values are ±0.2 degrees 2Θ.
4 . The crystalline trofinetide·xH 2 O of claim 1 further characterized as having a powder x-ray diffraction pattern with peaks at 22.3, 23.6, 25.3 and/or 28.1 degrees 2Θ+0.2 degrees 2Θ using Cu Kα radiation.
5 . The crystalline trofinetide·xH 2 O of claim 1 , characterized as having a powder x-ray diffraction pattern with d-spacings at 13.1, 7.7, 7.0, 6.4, and 5.3 Å using Cu Kα radiation.
6 . The crystalline trofinetide·xH 2 O of claim 1 , characterized as having an FT-Raman spectrum with peaks at 2989, 2934, 2883, 1685, 1637, 1459, and 930 cm −1 , wherein the cm −1 values are ±4 cm −1 .
7 . The crystalline trofinetide·xH 2 O of claim 1 , characterized as having a low frequency (LF) Raman spectrum with peaks at 13, 24, 67, and 77 cm −1 , wherein the cm −1 values are ±4 cm −1 .
8 . The crystalline trofinetide·xH 2 O of claim 1 , characterized as having a 13C solid-state nuclear magnetic resonance spectrum with peaks at 179.7, 177.9, 177.5, 177.2, 177.0, 165.3, 164.9, 164.8, 67.8, 67.4, 58.6, 58.2, 46.8, 40.3, 33.3, 25.3, 23.5, and 21.1 ppm, wherein the ppm values are ±3 ppm.
9 . The crystalline trofinetide·xH 2 O of claim 1 , characterized as having a 13C solid-state nuclear magnetic resonance spectrum with 18 peaks, wherein the Δ from the furthest downfield peak to: (i) the second furthest downfield peak is 1.8 ppm; (ii) the third furthest downfield peak is 2.2 ppm; (iii) the fourth furthest downfield peak is 2.5 ppm; (iv) the fifth furthest downfield peak is 2.7 ppm (v) the sixth furthest downfield peak is 14.4 ppm; (vi) the seventh furthest downfield peak is 14.8 ppm; (vii) the eighth furthest downfield peak is 14.9 ppm; (viii) the ninth furthest downfield peak is 111.9 ppm; (ix) the tenth furthest downfield peak is 112.3 ppm; (x) the eleventh furthest downfield peak is 121.1 ppm; (xi) the twelfth furthest downfield peak is 121.5 ppm; (xii) the thirteenth furthest downfield peak is 133.1 ppm; (xiii) the fourteenth furthest downfield peak is 139.4 ppm; (xiv) the fifteenth furthest downfield peak is 146.3 ppm; (xv) the sixteenth furthest downfield peak is 154.6 ppm; (xvi) the seventeenth furthest downfield peak is 156.2 ppm; and/or (xvii) the Δ from the furthest downfield peak to the furthest upfield peak is 158.6 ppm, or any combination thereof.
10 . The crystalline trofinetide·xH 2 O of claim 1 , characterized as having a melting point with an onset temperature of 71.71° C. and a peak temperature of 72.06° C. based on differential scanning calorimetry.
11 . The crystalline trofinetide·xH 2 O of claim 1 , characterized as having an infrared (IR) spectrum with peaks at 1678, 1636, 1589, 1525, 1214, and 1196 cm −1 , wherein the cm −1 values are ±4 cm −1 .
12 . The crystalline trofinetide·xH 2 O of claim 1 , characterized as having a near-infrared (NIR) spectrum with peaks at 5145, 4630, and 4423 cm −1 , wherein the cm −1 values are ±4 cm −1 .
13 . The crystalline trofinetide·xH 2 O of claim 1 having average particle size distribution of about 10 μm to about 500 μm.
14 . The crystalline trofinetide·xH 2 O of claim 1 , wherein x is about 2.5 to about 3.5.
15 . The crystalline trofinetide·xH 2 O of claim 1 , wherein x is about 2.
16 . The crystalline trofinetide·xH 2 O of claim 1 , wherein x is about 2.5.
17 . The crystalline trofinetide·xH 2 O of claim 1 , wherein x is about 3.
18 . The crystalline trofinetide·xH 2 O of claim 1 , wherein x is about 3.5.
19 . The crystalline trofinetide·xH 2 O of claim 1 , wherein x is about 4.
20 . A pharmaceutical composition comprising the crystalline trofinetide·xH 2 O of claim 1 and a pharmaceutically acceptable excipient.
21 . The pharmaceutical composition of claim 20 in granular form.
22 . An aqueous pharmaceutical formulation comprising the crystalline trofinetide·xH 2 O of claim 1 dissolved in water.
23 . The aqueous pharmaceutical formulation of claim 22 , wherein about 1 gram of crystalline trofinetide·xH 2 O is dissolved in each 5 mL of the water.
24 . A method of making the aqueous pharmaceutical formulation of claim 22 , the method comprising admixing the crystalline trofinetide·xH 2 O and water.
25 . A kit comprising the crystalline trofinetide·xH 2 O of claim 1 and instructions for dissolving crystalline trofinetide·xH 2 O in a water to provide an aqueous pharmaceutical formulation.
26 . The kit of claim 25 further comprising instructions for administering the aqueous pharmaceutical formulation to a subject having a disease, disorder or condition.
27 . The kit of claim 26 , wherein the disease, disorder or condition is traumatic brain injury.
28 . The kit of claim 26 , wherein the disease, disorder or condition is a neurodevelopmental disorder.
29 . The kit of claim 28 , wherein the neurodevelopmental disorder is Rett Syndrome, Fragile X Syndrome, or autism spectrum disorder.
30 . A method of treating a disease, disorder or condition in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 20 to the subject.
31 . The method of claim 30 , wherein the disease, disorder or condition is traumatic brain injury.
32 . The method of claim 30 , wherein the disease, disorder or condition is a neurodevelopmental disorder.
33 . The method of claim 32 , wherein the neurodevelopmental disorder is Rett Syndrome, Fragile X Syndrome, or autism spectrum disorder.
34 . The method of claim 30 , wherein the disease, disorder or condition is Rett Syndrome.
35 . A method of making the crystalline trofinetide·xH 2 O of claim 1 , the method comprising i) adding ethanol to an aqueous solution of trofinetide at about 25° C.; ii) cooling the solution to about 0° C.; and iii) isolating the solid thus obtained to give crystalline trofinetide·xH 2 O.
36 . The method of claim 35 , wherein the water: ethanol ratio is about 3:7 w/w.
37 . The crystalline trofinetide·xH 2 O of claim 1 , wherein x is about 2 to about 3.
38 . The crystalline trofinetide·xH 2 O of claim 1 , wherein x is about 2 to about 2.5.
39 . The crystalline trofinetide·xH 2 O of claim 1 , wherein x is about 2.5 to about 3.